February 15th 2025
Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.
2025 GU Satellite Symposia in San Francisco
February 13-14, 2025
Register Now!
Medical Crossfire®: Real World Strategies to Improve Therapeutic Durability and Outcomes in CLL
February 20, 2025
Register Now!
Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non-Smal...
February 27, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
NDA Submitted for Single-Agent Relugolix to Treat Prostate Cancer
April 21st 2020A New Drug Application (NDA) has been submitted to the FDA for single-agent relugolix for use as a treatment for men with advanced prostate cancer, according to Myovant Sciences, the developer of the oral GnRH receptor antagonist.
PARP Inhibitors Continue to Show Promise in Prostate Cancer Treatment
March 31st 2020The use of PARP inhibitors against DNA damage repair (DDR) alterations in prostate cancer is the first display of the potential for widespread precision medicine in the field, according to William K. Oh, MD, in a presentation during the 13th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.
Localized Bladder Cancer Treatment Continues to Change: Expert Weighs In
March 21st 2020Treatment options for patients with localized bladder cancer, beyond Bacillus Calmette-Guérin (BCG), are evolving as immunotherapies and novel agents are gaining traction in the management of this population, according to John P. Sfakianos, MD.
Ilixadencel Added to Sunitinib May Improve RCC Outcomes
February 15th 2020The addition of the off-the-shelf cancer immune primer ilixadencel to sunitinib (Sutent) trended toward a benefit in overall survival (OS) compared with sunitinib alone as a first-line treatment for patients with newly diagnosed metastatic renal cell carcinoma (RCC).
Increasing Prostate Cancer Screening Takes a Team Approach
February 6th 2020With the advent of targeted therapy, understanding the genetic components of a patient's disease has become critical in oncology. As the role of genetic testing in prostate cancer has grown, the field is also overcoming hurdles with making it more widespread, said Thomas J. Polascik, MD.
Immunotherapy Combos Are Now Standard of Care for Advanced RCC
January 13th 2020The standard of care for treatment-naïve patients with advanced renal cell carcinoma (RCC) has shifted from a single-agent VEGF TKI to a checkpoint inhibitor plus either a VEGF TKI or a CTLA-4 inhibitor, explained David F. McDermott, MD.
Next-Generation Imaging Will Change Prostate Cancer Paradigm
January 11th 2020Novel next-generation imaging modalities have greater visibility than conventional imaging tools, leading to higher detection rates and earlier treatment of early recurrences and metastatic disease among men with prostate cancer, explained Hussein Aoun, MD.
FDA Approves Pembrolizumab for BCG-Unresponsive, High-Risk Bladder Cancer
January 9th 2020The FDA approved pembrolizumab (Keytruda) for the treatment of patients who are unresponsive to Bacillus Calmette-Guerin (BCG) treatment with high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
New Agents Are Revamping Prostate Cancer Treatment
December 20th 2019Three pivotal trials demonstrating improved metastasis-free survival (MFS) with 3 different oral antiandrogen agents in combination with androgen deprivation therapy (ADT) have led to FDA approvals that have transformed the treatment paradigm in nonmetastatic castration-resistant prostate cancer (CRPC), said Elisabeth I. Heath, MD, FACP.
FDA Grants Pembrolizumab Priority Review for High-Risk Bladder Cancer
December 2nd 2019The FDA has granted a priority review designation to pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)–unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.
Expert Discusses Genetic Predisposition to Prostate Cancer in Racially Diverse Patient Populations
October 31st 2019Genetic testing in cancer care is a relatively new element of the field, but some experts are looking to it to help prevent and understand prostate cancer in racially diverse populations.